ReviewJournal of clinical and experimental hepatology
Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy.The Cochrane database of systematic reviews · 2026Pooled it
- Sarcopenia and Skeletal Muscle Dysfunction in Liver Cirrhosis: Clinical Perspectives of Myostatin Inhibition.Biomedicines · 2026Review
- Association between specialized nutrition support and 90-day mortality relative to standard of care in malnourished adults with decompensated cirrhosis: A retrospective cohort study.JPEN. Journal of parenteral and enteral nutrition · 2026Article
- Management of Refractory Hepatic Encephalopathy.Digestive diseases and sciences · 2026Review
- Outcomes after TIPS in patients with cirrhosis and sarcopenia: A systematic review and meta-analysis.JHEP reports : innovation in hepatology · 2026Article
- Impact of quantitative dietary guidance on postoperative outcomes in patients undergoing transjugular intrahepatic portosystemic shunt surgery: a retrospective cohort study.Frontiers in nutrition · 2026Article
- Sarcopenia as a novel biomarker for predicting TIPS outcomes in cirrhotic patients with refractory ascites: Mechanisms linking muscle loss, metabolic dysregulation, and portal hemodynamics.Hepatology forum · 2026Article
- Neurofilament light chain proteins are a sensitive biomarker of neuronal damage in cirrhotic patients with hepatic encephalopathy.Frontiers in molecular biosciences · 2026Article
- Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis.World journal of hepatology · 2025Article
- Attenuating hyperammonemia preserves protein synthesis and muscle mass via restoration of perturbed metabolic pathways in bile duct-ligated rats.Metabolic brain disease · 2025Article
- Blood ammonia concentration measurement - effects of sampling site and cirrhosis during induced hyperammonaemia.Metabolic brain disease · 2024Article
- Article
- The Value of Ammonia as a Biomarker in Patients with Cirrhosis.Seminars in liver disease · 2024Review
- Future Therapies of Hepatic Encephalopathy.Clinics in liver disease · 2024Review
- Transjugular Intrahepatic Portosystemic Shunt Placement: Effects on Nutritional Status in Cirrhotic Patients.Journal of clinical medicine · 2023Review
- Role of ammonia in NAFLD: An unusual suspect.JHEP reports : innovation in hepatology · 2023Review
- Radiological assessment of skeletal muscle index and myosteatosis and their impact postoperative outcomes after liver transplantation.Radiology and oncology · 2023Article
- Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties.World journal of gastroenterology · 2023Review
- Cognitive Impairment and Physical Frailty in Patients With Cirrhosis.Hepatology communications · 2022Article
- The neurogliovascular unit in hepatic encephalopathy.JHEP reports : innovation in hepatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an important burden in liver cirrhosis representing a negative prognostic factor for mortality. Moreover, sarcopenia is an independent predictor of complications in patients with liver cirrhosis, including Hepatic Encephalopathy (HE). An association between sarcopenia and HE in liver cirrhosis has been reported in recent studies, indeed both these complications often affect patients with advanced liver cirrhosis and may exert a synergic effect in deteriorating patients' outcome. Episodes of HE occur more often in patients with muscle depletion. The rationale for these finding is based on the role played by muscle in ammonia detoxification due to the inability of urea synthesis in the cirrhotic liver. Consequently, muscle depletion may have relevant implications in favoring hyperammonemia and HE. At the same time hyperammonemia has been found to impair muscle protein synthesis through myostatin down-regulation. From this point of view, modulation of diet and amelioration of nutritional status and muscle mass can be considered a potential goal to prevent this vicious circle and improve the cognitive impairment in cirrhotic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.